healthcare · FDA 21 CFR Part 11 · GCP ICH E6 · EU AI Act Annex III
Pharma / Clinical Trials
21 CFR Part 11 already requires what Velaru does — not AI safety, compliance
—NYDFS AI guidance + Local Law 144 enforcement
Regulatory exposure — commonly overlooked:
Sponsors using vendor AI for protocol deviation detection — sponsor owns FDA finding, vendor owns nothing. · Local Law 144 requires annual bias audit — Velaru receipts are continuous audit, not annual snapshot.
TAM / Exposure
$200B+ pharma R&D · AI in trial design exploding
Insurance lines
Product liability · Clinical trial E&O
Exhibit authority
New York AI Governance Pack — 21 CFR Part 11 Clinical AI Audit Pack
Global leaders
FDA · Pfizer · IQVIA · Veeva · EMA · NYDFS · NYC DCWP · Goldman Sachs
483 observations
FDA inspection: show audit trail for AI-flagged deviation — altered records = criminal referral pattern.
ICH E6 GCP
AI-assisted monitoring must be in validation documentation — post-hoc PowerPoint fails.
Trial insurance
Clinical trial insurers now ask AI governance questionnaire — receipts beat questionnaires.
[New York] Financial capital
NYDFS regulates insurers AND banks — same receipt primitive for both books.
[New York] Hiring audit law
NYC AEDT law is template for other cities — receipt architecture scales municipally.
[Text / Chat] Modality hook
Baseline — all frameworks apply to text decisions.
7 mandate layers (live)
Regulatory ClockCountdown to operative regulatory deadline — NAIC adoption, GSE mandate, EU transposition.Open →
Domain ClassifierIndustry-specific SAFE/CRISIS/VIOLATION with regulatory framework mapping.Open →
Exhibit / Filing PackRegulator-ready external validation — NAIC Exhibit D, Fannie QC, EU FRIA, FDA Part 11.Open →
Mandate RegistryEnroll deployers/insureds under vertical-specific governance mandate.Open →